About LIMIT-HPV

The main objectives of this study are:

1. To evaluate the efficacy of carrageenan in reducing type-specific anal HPV incidence, i.e., in preventing infections by new HPV types in sexually active men who have sex with men.
2. To evaluate the efficacy of carrageenan in reducing type-specific anal HPV prevalence, i.e., in accelerating clearance of existing infections in sexually active men who have sex with men
3. To compare the efficacy of carrageenan for type-specific prevention and clearance of anal HPV infections among men who have sex with men with and without HIV, i.e., to evaluate whether carrageenan is equally effective among these subgroups
4. To assess the safety and tolerability of the proposed gel and patient adherence to the intervention, i.e., the parameters important for future clinical use.